Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Apyridine P
- Development stage
- Unknown
- Lead developer
- Primus Remedies
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Apyridine P is a fixed-dose combination oral tablet containing flupirtine maleate (100 mg) and paracetamol (325 mg), developed and marketed by Primus Remedies. It is indicated for the short-term management of acute and chronic pain, including post-surgical pain, dental pain, pain associated with muscle spasms, cancer pain, neuropathic pain, low back pain, and migraine. Flupirtine acts as a selective neuronal potassium channel opener (SNEPCO) that activates Kv7 (KCNQ) potassium channels, leading to neuronal membrane hyperpolarization and reduced excitability, while also indirectly antagonizing NMDA receptors and modulating GABA-A receptors to provide muscle relaxation. Paracetamol complements this by inhibiting prostaglandin synthesis in the central nervous system through the cyclooxygenase (COX) pathway, thereby reducing pain and fever.
- Brand names
- Apyridine PApyridine-P
- Other names
- Flupirtine and ParacetamolFlupirtine maleate and ParacetamolFlupirtine maleate + ParacetamolFlupirtine + Paracetamol
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)KCNQ2 (Potassium voltage-gated channel subfamily KQT member 2)KCNQ3 (Potassium voltage-gated channel subfamily Q member 3)KCNQ5 (Potassium voltage-gated channel subfamily KQT member 5)
Beyond the preview
Go deeper on Apyridine P.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apyridine P.